表紙
市場調査レポート

世界における抗生物質市場

Global Antibiotics Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 312950
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界における抗生物質市場 Global Antibiotics Market 2014-2018
出版日: 2014年09月17日 ページ情報: 英文 96 Pages
概要

世界における抗生物質市場は、2013年から2018年の間、1.41%のCAGRで拡大することが見込まれています。

当レポートでは、世界における抗生物質市場の現況と将来予測、作用機序、化学的分類別の動向、市場の成長要因と課題、主要ベンダーの分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • 抗生物質の米国市場
  • 抗生物質の欧州市場
  • 抗生物質のアジア市場
  • ファイブフォース分析

第7章 作用機序別の市場区分

第8章 化学的分類別の市場区分

第9章 地理区分

第10章 購入基準

第11章 市場成長因子

第12章 成長因子とその影響

第13章 市場の課題

第14章 成長因子と課題の影響

第15章 市場動向

第16章 動向とその影響

第17章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第18章 主要ベンダーの分析

  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Co.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

第19章 関連レポート

目次
Product Code: IRTNTR4193

About Antibiotics

Antibacterial drugs are chemical compounds used to kill or inhibit the growth of bacteria. The term "antibiotic" is often used synonymously with antibacterial; however, the term "antibiotic" was originally coined to refer to the antibacterial compounds of microbial origin. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. It can be bacteriostatic or bactericidal in nature. Antibiotics are medicines that are used to treat infections caused by bacteria (e.g., respiratory tract infections). Antibiotics work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. Antibiotics either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).

TechNavio's analysts forecast the Global Antibiotics market to grow at a CAGR of 1.41 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Antibiotics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various antibiotics for human use. The Global Antibiotics market can be divided into eight segments: Beta-lactams, Macrolides, Aminoglycosides, Phenicols, Quinolones, Sulfonamides, Tetracyclines, and Others.

TechNavio's report, the Global Antibiotics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Antibiotics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Bayer HealthCare
  • Bristol Myers Squibb
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Takeda Pharmaceutical

Market Driver

  • Increased Aging Population

For a full, detailed list, view our report

Market Challenge

  • Emergence of Drug-resistant Strains

For a full, detailed list, view our report

Market Trend

  • Increase in Demand for Antibiotics

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05.Introduction

06.Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Antibiotics Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. Antibiotics Market in Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Antibiotics Market in Asia
    • 06.5.1. Market Size and Forecast
  • 06.6. Five Forces Analysis

07. Market Segmentation by Mechanism of Action

  • 07.1. Introduction
  • 08. Market Segmentation by Chemical Class
    • 08.1. Market Segmentation by Drug Origin

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. AstraZeneca plc
    • 18.1.1. Key Facts
    • 18.1.2. Business Description
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Strategy
    • 18.1.5. Revenue by Business Segmentation
    • 18.1.6. Revenue Comparison 2011-2013
    • 18.1.7. Sales Revenue by Geographical Segmentation
    • 18.1.8. Key Developments
    • 18.1.9. SWOT Analysis
    • 18.1.10. Strengths
    • 18.1.11. Weaknesses
    • 18.1.12. Opportunities
    • 18.1.13. Threats
  • 18.2. GlaxoSmithKline plc
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Pipeline Products
    • 18.2.7. Business Strategy
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
    • 18.2.10. Strengths
    • 18.2.11. Weaknesses
    • 18.2.12. Opportunities
    • 18.2.13. Threats
  • 18.3. Eli Lilly and Co.
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis
    • 18.3.9. Strengths
    • 18.3.10. Weaknesses
    • 18.3.11. Opportunities
    • 18.3.12. Threats
  • 18.4. Johnson & Johnson
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2013
    • 18.4.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.4.5. Geographical Segmentation by Revenue 2013
    • 18.4.6. Business Strategy
    • 18.4.7. Recent Developments
    • 18.4.8. SWOT Analysis
    • 18.4.9. Strengths
    • 18.4.10. Weaknesses
    • 18.4.11. Opportunities
    • 18.4.12. Threats
  • 18.5. Novartis AG
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation by Revenue 2013
    • 18.5.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.5.5. Sales by Geography
    • 18.5.6. Business Strategy
    • 18.5.7. Key Developments
    • 18.5.8. SWOT Analysis
    • 18.5.9. Strengths
    • 18.5.10. Weaknesses
    • 18.5.11. Opportunities
    • 18.5.12. Threats
  • 18.6. Pfizer Inc.
    • 18.6.1. Key Facts
    • 18.6.2. Business Description
    • 18.6.3. Business Segmentation
    • 18.6.4. Revenue by Business Segmentation
    • 18.6.5. Revenue Comparison 2012KKKKK and 2013
    • 18.6.6. Sales by Geography
    • 18.6.7. Business Strategy
    • 18.6.8. Key Developments
    • 18.6.9. SWOT Analysis
    • 18.6.10. Strengths
    • 18.6.11. Weaknesses
    • 18.6.12. Opportunities
    • 18.6.13. Threats
  • 18.7. Sanofi
    • 18.7.1. Key Facts
    • 18.7.2. Business Overview
    • 18.7.3. Business Segmentation by Revenue 2013
    • 18.7.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.7.5. Geographical Segmentation by Revenue 2013
    • 18.7.6. Business Strategy
    • 18.7.7. Key Developments
    • 18.7.8. SWOT Analysis
    • 18.7.9. Strengths
    • 18.7.10. Weakness
    • 18.7.11. Opportunities
    • 18.7.12. Threats

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Antibiotics Market 2013-2018 (US$ million)
  • Exhibit 3: Antibiotics Market in the US 2013-2018 (US$ million)
  • Exhibit 4: Antibiotics Market in Europe 2013-2018 (US$ million)
  • Exhibit 5: Antibiotics Market in Asia 2013-2018 (US$ million)
  • Exhibit 6: Challenges Related to Antibiotic Development
  • Exhibit 7: Global Antibiotics Market Segmentation by Mechanism of Action
  • Exhibit 8: Global Antibacterial Drugs Market Segmentation by Chemical Class
  • Exhibit 9: Cephalosporin Segmentation by Generation of Drugs
  • Exhibit 10: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
  • Exhibit 11: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
  • Exhibit 12: Global Antibacterial Drugs Market Segmentation by Drug Origin
  • Exhibit 13: Global Antibiotics Market by Geographical Segmentation 2013
  • Exhibit 14: J&J Market Sales by Therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 15: J&J Market Sales by Major Franchise (Medical Devices and Diagnostics) 2013
  • Exhibit 16: Abbott Laboratories by Revenue 2013
  • Exhibit 17: AstraZeneca plc: Business Segmentation
  • Exhibit 18: AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 19: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 20: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 21: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 22: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 23: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 24: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 25: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 26: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 27: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 28: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 29: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 30: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 31: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 32: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 33: Novartis AG: Sales by Geography 2013
  • Exhibit 34: Pfizer Inc.: Business Segmentation
  • Exhibit 35: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 36: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 37: Pfizer Inc.: Revenue by Geography 2013
  • Exhibit 38: Sanofi: Business Segmentation by Revenue 2013
  • Exhibit 39: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 40: Sanofi: Geographical Segmentation by Revenue 2013
Back to Top